The NOA-04 trial and validation cohorts in NOA-08 and the German Glioma Network indicated that methylation of MGMT promoter improved outcomes in patients carrying wild-type IDH.[24] However, the present study offered no definitive evidence suggesting that IDH mutations increased the benefit of adjuvant TMZ chemotherapy. Here, IDH2 is linked to glioma.